Crohn's disease trials in China

In China 73 Also abroad 422

73 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Beijing, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou, Hangzhou, Hefei, Huaian, Huizhou, Kunming, Nanjing, Shanghai, Shaoguan, Shenzhen, Shijiazhuang, Shiyan, Suining, Taizhou, Wuhan, Wuxi, Xiamen, Xi'an, Yangzhou, Zhengzhou, Zhenjiang
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
Phase 2Taking people
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Where
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen, Zhenjiang
Age
18 years to 80 years
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483073 · EU 2025-524112-11-00
Phase 2Taking people
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Where
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen, Zhenjiang
Age
18 years to 80 years
People
60 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07483099
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
Phase 2/3Taking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Huizhou, Jinhua, Lanzhou, Luoyang, Luzhou, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Shenzhen, Suzhou, Wenzhou, Wuhan, Xiamen, Yangzhou, Zhuzhou, Zunyi
Age
18 years and over
People
1,092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
Phase 4Taking people
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
Where
Guangzhou, Hangzhou, Hefei, Shanghai
Age
18 years and over
People
78
Run by
Xian-Janssen Pharmaceutical Ltd.
See details and how to joinNCT07310095
Phase 3Taking people
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Where
Changzhou, Chongqing, Fuzhou, Guangzhou, Nanjing, Wuhan
Age
18 years and over
People
530 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07499232
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Hangzhou, Hefei, Huai'an, Lanzhou, Nanjing, Ningbo, Shanghai, Wenzhou, Wuhan, Wuxi, Xiamen, Zhuzhou
Age
18 years and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
Phase 3Taking people
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Where
Beijing, Changsha, Changzhou, Foshan, Fuzhou, Guangzhou, Haerbin, Hangzhou, Hefei, Huizhou, Kunming, Lanzhou, Nanchang, Nanjing, Nanyang, Ningbo, Qingyuan, Quzhou, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wenzhou, Wuhan, Wuhu, Xuzhou, Yancheng, Yantai, Yinchuan, Zhenjiang, Zhuhai
Age
18 years to 80 years
People
408
Run by
Takeda
See details and how to joinNCT05837897
Phase 2Taking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Changsha, Changzhou, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang, Suzhou, Wuhan, Xiamen, Zhejiang
Age
18 years to 75 years
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
Phase 2Taking people
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
Where
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
Age
18 years to 75 years
People
99 worldwide
Run by
Sanofi
See details and how to joinNCT06958536 · EU 2024-517016-30-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Chengdu, Ganzhou, Guangzhou, Haikou, Huai'an, Huizhou, Jinhua, Kunming, Nanchang, Shanghai, Shenyang, Shijiazhuang, Suzhou, Xiamen, Xi'an, Zhenjiang
Age
16 years to 80 years
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Changsha, Changshu, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Huizhou, Jinan, Jingzhou, Jinhua, Luzhou, Mianyang, Nanjing, Qingdao, Qingyuan, Shanghai, Shenzhen, Suzhou, Taizhou, Wenzhou, Wuhan, Wuxi, Xiamen, Yangzhou
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
Phase 3Taking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Guangzhou, Huizhou, Shanghai, Wuxi
Age
16 years to 80 years
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Shenyang, Zhengzhou
Age
2 years to 17 years
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Huizhou, Nanchang, Nanning, Ningbo, Shanghai, Shenzhen, Taizhou, Wuhan, Wuxi, Xiamen, Zhengzhou, Zhuzhou
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
Phase 4Taking people
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Where
Beijing
Age
6 years to 17 years
People
30
Run by
Taizhou Mabtech Pharmaceutical Co.,Ltd
See details and how to joinNCT05906576
Phase 1Taking people
A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease
Where
Hangzhou
Age
18 years to 55 years
People
88
Run by
Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07758101
Phase 4Taking people
Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®
Where
Fuyang, Huaian, Meihekou, Shanghai, Yancheng, Zhengzhou, Zhoukou
Age
18 years to 70 years
People
50
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07663526
No phaseTaking people
Endoscopic Stricturotomy Versus Balloon Dilation for Small Bowel Fibrotic Strictures in Crohn's Disease
Where
Guangzhou
Age
18 years to 70 years
People
244
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07833332
No phaseTaking people
Prediction of Postoperative Recurrence in Crohn's Disease
Where
Guangzhou
Age
18 years to 70 years
People
250
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07824791
Phase 4Taking people
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
Where
Guangzhou
Age
6 years to 17 years
People
30
Run by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07564505
No phaseTaking people
Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease
Where
Guangzhou
Age
18 years and over
People
300
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07504510
No phaseTaking people
Fecal Microbiota Transplantation in Pediatric Crohn's Disease
Where
Wuhan
Age
2 years to 16 years
People
40
Run by
Biao Zou
See details and how to joinNCT05321745
No phaseTaking people
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
Where
Wuhan
Age
2 years to 16 years
People
50
Run by
Tongji Hospital
See details and how to joinNCT05321758